[Treatment of KSHV infection].
Onda
Junko
J
International Medical Center of Japan, AIDS Clinical Center.
Oka
Shinichi
S
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D018943:Anthracyclines / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage; D023241:Antiretroviral Therapy, Highly Active; D019288:Herpesvirus 8, Human; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage; D017239:Paclitaxel / Q000008:administration & dosage; D011878:Radiotherapy; D011994:Recombinant Proteins; D012514:Sarcoma, Kaposi / Q000150:complications / Q000628:therapy* / Q000821:virology; D013792:Thalidomide / Q000008:administration & dosage; D014747:Vinblastine / Q000008:administration & dosage
D020533:Angiogenesis Inhibitors; D018943:Anthracyclines; D000970:Antineoplastic Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D013792:Thalidomide; D014747:Vinblastine; D017239:Paclitaxel